Legend Biotech (LEGN) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xenon Pharmaceuticals (XENE) has outperformed Legend Biotech (LEGN) over the past year, losing 7.9% versus a loss of 41.9%. Over five years, XENE leads with a +7.4% price change compared with -64.0% for LEGN. Legend Biotech is the larger company by market cap ($3.64 billion vs $3.50 billion), about 1.0 times the size.
Legend Biotech converts more of its revenue into profit, with a net margin of -28.8% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LEGN | XENE |
|---|---|---|
| Share price | $18.71 | $36.16 |
| Market cap | $3.64B | $3.50B |
| 1-day change | -2.14% | -0.69% |
| YTD return | -13.94% | -19.32% |
| 1-year return | -41.91% | -7.87% |
| 5-year return | -63.96% | +7.43% |
| Forward P/E | 17.82 | — |
| EPS (TTM) | $-0.52 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03B | $7.50M |
| Revenue growth (YoY) | +64.04% | — |
| Net income (latest FY) | $-296.80M | $-345.91M |
| Gross margin | 61.41% | — |
| Operating margin | -13.27% | -4974.27% |
| Net margin | -28.85% | -4612.13% |
| 52-week high | $37.50 | $72.66 |
| 52-week low | $16.24 | $35.06 |
| Distance from 52-week high | -50.11% | -50.23% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +148.53% | +102.90% |
| Average volume | 2.37M | 1.43M |
| Shares outstanding | 194.49M | 96.84M |
| Employees | 3,200 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XENE has outperformed LEGN by 34.0 percentage points over the past year.
- Legend Biotech is more profitable, keeping -28.8 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
LEGN vs XENE FAQ
Which is bigger, Legend Biotech or Xenon Pharmaceuticals?
Legend Biotech (LEGN) is larger, with a market capitalization of $3.64B compared with $3.50B for Xenon Pharmaceuticals (XENE).
Which stock has performed better over the past year, LEGN or XENE?
XENE returned -7.87% over the past 12 months, compared with -41.91% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Legend Biotech and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.